KalVista Pharmaceuticals (KALV) Soars 11.37% on Positive Analyst Recommendations

KalVista Pharmaceuticals, Inc. (KALV) shares surged 0.62% today, marking an eighth consecutive day of gains and an 11.37% increase over the past eight days. The stock price reached its highest level since September 2024, with an intraday gain of 3.08%.

Analyst recommendations have played a significant role in the recent performance of KalVista Pharmaceuticals. On March 26, 2025, Jones Trading reiterated a positive outlook for the company, suggesting a stock price increase to $13.15, which is a 1.2% rise from the previous price. This recommendation likely contributed to the upward momentum in the stock price.

Additionally, TD Cowen initiated coverage of KalVista Pharmaceuticals on January 7, 2025, with a "Buy" rating and a target price of $30.00. This favorable view from analysts has likely influenced investor sentiment, driving the stock price higher. The combination of these positive analyst recommendations has created a bullish environment for KalVista Pharmaceuticals, contributing to its recent stock price gains.